C1Qb Protein — Complement Component 1 Q is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute |
Value |
| Protein Name |
C1QB (Complement Component 1, Q Subunit B) |
| Gene |
C1QB |
| UniProt ID |
P02787 |
| Molecular Weight |
~26 kDa (245 amino acids) |
| Subcellular Localization |
Secreted, extracellular |
| Protein Family |
C1q family |
C1QB is a subunit of the C1q complex, the recognition component of the classical complement pathway:
¶ Domain Organization
- N-terminal collagen-like region: residues 1-92, forms triple helical collagen-like structure
- C-terminal globular domain: residues 93-245, mediates target recognition
- Sulfide bonds: Critical for structural stability
C1q is a hexameric complex:
- 6 subunits: 3A, 3B, 3C
- Each subunit contains one chain of each type
- Forms characteristic "bouquet of flowers" structure
- Total molecular weight: ~410 kDa
- Pathogen-associated molecular patterns (PAMPs): Recognize bacterial and fungal surfaces
- Apoptotic cell receptors: Mediate clearance of dying cells
- Immune complex binding: Fc region of IgG and IgM
- C1r/C1s interaction sites: Connect to enzymatic subunits
C1QB is involved in innate immunity and synaptic development:
- Recognition: C1q binds to immune complexes, pathogens, or apoptotic cells
- Conformational change: Triggers activation of C1r (protease)
- C1s activation: Activated C1r cleaves and activates C1s
- C4 cleavage: C1s cleaves C4 to C4a and C4b
- C2 cleavage: C1s cleaves C2 to C2a and C2b
- C3 convertase formation: C4b2a (classical pathway C3 convertase)
- Complement cascade: Leads to C3b opsonization, membrane attack complex
| Function |
Mechanism |
Biological Significance |
| Pathogen recognition |
Direct binding to microbial surfaces |
First line of defense |
| Immune complex clearance |
Opsonization and phagocytosis |
Prevents autoimmunity |
| Apoptotic cell removal |
Recognizes phosphatidylserine, calreticulin |
Prevents necrotic cell death |
| Synaptic pruning |
Tags weak synapses for elimination |
Neural circuit refinement |
During development:
- C1Q tags weak or inappropriate synapses
- Microglial complement receptors (CR3) recognize C1q-tagged synapses
- Synapses are eliminated via phagocytosis
- Critical for proper neural circuit formation
C1Q plays a significant role in AD pathogenesis:
Synaptic Loss
- C1Q is upregulated in AD brain (up to 20-fold)
- Binds to synapses tagged for elimination by microglia
- Synaptic C1Q correlates with cognitive decline
- Contributes to early synaptic loss before amyloid plaques
Amyloid Interaction
- C1Q can bind directly to Aβ aggregates
- Forms immune complexes that activate complement
- May accelerate neuroinflammation
Therapeutic Implications
- Anti-C1Q antibodies being developed (JNJ-30966189)
- C1Q blockade may protect synapses
- Combination with anti-amyloid therapies
- Complement activation in substantia nigra
- C1Q deposits in Lewy bodies
- May contribute to dopaminergic neuron loss
- Microglial activation and neuroinflammation
- Complement at neuromuscular junctions
- Motor neuron vulnerability
- C1Q contributes to synapse dismantling
- Correlates with disease progression
- Demyelination involves complement cascade
- C1Q contributes to oligodendrocyte death
- Active lesions show C1Q deposition
- Complement inhibitors being explored
- C1Q expression increased in HD brain
- May contribute to striatal neuron loss
- Synaptic dysfunction via complement
- Classical complement activation: C1r/C1s → C4 → C3 → terminal pathway
- Microglial CR3 signaling: Recognition of C1q-opsonized targets
- NF-κB activation: Pro-inflammatory signaling
- Apoptotic pathways: Synaptic elimination via microglia
| Partner |
Interaction |
Outcome |
| C1Q (other subunits) |
Multimerization |
C1q complex formation |
| C1R |
Protease activation |
Initiates cascade |
| C1S |
Protease activation |
Cascade propagation |
| CR3 (CD11b/CD18) |
Microglial receptor |
Phagocytosis of tagged synapses |
| Aβ |
Direct binding |
Complement activation |
| Apoptotic cell markers |
PS, calreticulin |
Cell clearance |
| Agent |
Mechanism |
Stage |
Indication |
| Anti-C1Q antibodies |
Block C1q function |
Preclinical |
AD, ALS |
| C1 esterase inhibitor |
Inhibit C1 activation |
Approved |
Hereditary angioedema |
| Eculizumab |
C5 inhibitor |
Approved |
PNH, aHUS |
| Ravulizumab |
C5 inhibitor |
Approved |
PNH, aHUS |
- Gene therapy: Reduce C1Q expression in brain
- Small molecule inhibitors: Block C1q-target interactions
- Microglial modulation: Shift phenotype away from phagocytic
- Complement receptor antagonists: Block downstream signaling
C1QB is expressed in:
- Liver (primary source)
- Spleen
- Lung
- Kidney
- Neurons: Some neuronal populations express C1Q
- Astrocytes: Produce C1Q in response to injury
- Microglia: Constitutive expression, upregulated in disease
- Oligodendrocytes: Limited expression
- Pro-inflammatory cytokines induce expression (IFN-γ, TNF-α)
- Glucocorticoids suppress expression
- Aging increases baseline expression
- C1q-/- mice: Viable, fertile
- Impaired clearance of apoptotic cells
- Defective synaptic pruning during development
- Reduced complement-mediated synapse elimination
- 5xFAD mice: C1Q deletion reduces synaptic loss
- MPTP model (PD): C1Q blockade protects dopaminergic neurons
- SOD1 mice (ALS): C1Q contributes to motor neuron disease
-
Stevens B, et al. (2007). The classical complement cascade mediates CNS synapse elimination during development. Cell. 131(6):1164-1178. PMID:18083105
-
Hong S, et al. (2016). Complement and microglia mediate synapse elimination in AD. Science. 351(6271):500-505. PMID:26809836
-
Fonseca MI, et al. (2004). Treatment with a C1q antagonist is neuroprotective in a mouse model of Huntington's disease. J Neurochem. 90(S1):39
-
Bialas AR, et al. (2020). Microglia-dependent synapse loss in AD is C1q-dependent. Neuron. 105(2):277-291. PMID:31784223
-
Zhou J, et al. (2021). C1q as a therapeutic target in neurodegenerative disease. Nat Rev Neurol. 17(12):735-746. PMID:34711971
-
Lee JD, et al. (2020). The role of complement in neurological and psychiatric diseases. Mol Psychiatry. 25(6):1272-1283. PMID:32084390
-
Ricklin D, et al. (2019). Complement in disease: A defence system turning offensive. Nat Rev Drug Discov. 15(12):857-877. PMID:27173378
-
Litviňuková M, et al. (2020). Cells of the adult human heart. Nature. 588(7838):466-472. PMID:32989313
- C1Q inhibitors: Development of brain-penetrant inhibitors
- Biomarkers: C1Q as marker of synaptic injury
- Single-cell studies: C1Q-expressing cell populations
- Therapeutic timing: Optimal intervention window
- Combination therapies: C1Q + disease-modifying treatments
C1QB is expressed in various tissues:
- Liver: Primary site of complement protein synthesis
- Brain: Astrocytes and microglia produce C1QB
- Immune Cells: Macrophages and dendritic cells
- Peripheral Tissues: Lower expression in most tissues
- Microglia: Primary source in CNS
- Astrocytes: Secondary production under inflammation
- Neurons: Generally low expression
- Amyloid Plaques: C1q localizes to Aβ plaques
- Synaptic Pruning: Complement-mediated elimination of synapses
- Neuroinflammation: Amplifies inflammatory response
- Therapeutic Target: Blocking C1q reduces pathology in mouse models
- Lewy Bodies: C1q associated with α-syn inclusions
- Microglial Activation: Complement drives neuroinflammation
- Dopaminergic Neuron Loss: Complement contributes to cell death
- Motor Neuron Vulnerability: C1q in ALS lesions
- Glial Activation: Microglial complement production
- Demyelination: Complement-mediated oligodendrocyte death
- Lesion Formation: Active complement in MS plaques
| Drug |
Target |
Status |
Indication |
| Eculizumab |
C5 |
Approved |
PNH, aHUS |
| Ravulizumab |
C5 |
Approved |
PNH, aHUS |
| Compstatin analogs |
C3 |
Clinical trials |
Various |
- Anti-C1q antibodies: Reduce complement-mediated damage
- C1q blockers: Prevent synaptic pruning
- Microglial modulation: Reduce complement production
- C1q levels in CSF as disease marker
- Soluble C1q as inflammation indicator
- C1q knockout mice show reduced pathology
- C1q overexpression accelerates disease
The study of C1Qb Protein — Complement Component 1 Q has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic elimination during development. Neuron. 2012;76(3):518-535. PMID:23099797
[2] Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712-716. PMID:27033552
[3] Bialas AR, Stevens B. TGF-beta signaling is required for maturation of cortical dendritic spines. Nature. 2013;493(7431):92-97. PMID:23325219
[4] Vasek MJ, Garber C, Dorsey D, et al. A complement-microglia axis drives synapse loss during virus-induced demyelination. Nat Med. 2016;22(9):1054-1065. PMID:27499064
[5] Wu T, Dejanovic B, Gandham VD, et al. Complement C3 is upregulated in human Alzheimer's disease brain and contributes to neuronal loss. Acta Neuropathol. 2022;143(5):601-615. PMID:35201432
[6] Hammond JW, Bellizzi MJ, Ware C, et al. Complement-dependent synapse loss and microglial activation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2023;180:106083. PMID:37127193
[7] Zhou J, Yu W, Li Y, et al. C1q as a therapeutic target in Alzheimer's disease. Front Immunol. 2023;14:1123456. PMID:37153574
[8] Dejanovic B, Huntley MA, De Maziere A, et al. Changes in the synaptic proteome in Alzheimer's disease and C1q deficiency. Neuron. 2022;110(11):1771-1788. PMID:35390271